Abstract：【Objective】To explore the application effect of high-dose oxycodone sustained-release tablets in moderate and severe pain in patients with advanced digestive system tumors.【Methods】 The clinical data of 60 patients with moderate and severe pain of advanced digestive system tumors treated in the oncology department of Xi'an Fouth Hospital from January 2017 to April 2020 were analyzed retrospectively. The patients in the control group were treated with conventional dose of oxycodone sustained-release tablets (the initial dose was 10 mg/therapy),and the patients in the observation group were treated with high-dose oxycodone sustained-release tablets (the initial dose was 40 mg/therapy). The changes of pain degree (NRS),immune function [T cell subsets (CD3+,CD4+,CD8+) and natural killer cells (NK)],anxiety and depression (SAS/SDS),coping style (Medical Coping Questionnaire,MCMQ) and adverse reactions were compared between the two groups. 【Results】Before treatment,there was no significant difference in NRS score,CD3+,CD4+,CD8+,CD4+/CD8+,NK cell level,SAS,SDS score,yield,escape and face score in MCMQ between the two groups (P>0.05); After treatment,the NRS scores,CD3+,CD4+,CD4+/CD8+,NK cell levels,SAS,SDS scores,yield and escape scores of the two groups were significantly lower than those before treatment (P<0.05); The level of CD8+ was significantly higher than that before treatment,and the NRS score,CD3+,CD4+, CD4+/CD8+,NK cell level,SAS,SDS score,yield and escape score of the observation group were significantly lower than those of the control group (P<0.05),and the level of CD8+ was higher than that of the control group (P<0.05). 【Conclusion】High dose oxycodone sustained release tablets can effectively alleviate the pain of patients with moderate and severe pain in advanced digestive system tumors,enhance immune function,reduce the degree of anxiety and depression,and the safety is not affected.
郭争社, 何印斌. 大剂量羟考酮缓释片在晚期消化系统肿瘤中重度疼痛患者中的应用效果[J]. 医学临床研究, 2022, 39(6): 913-916.
GUO Zheng-she, HE Yin-bin. Application of High-Dose Oxycodone Sustained-Release Tablets in Moderate and Severe Pain in Patients with Advanced Digestive System Tumors. JOURNAL OF CLINICAL RESEARCH, 2022, 39(6): 913-916.
[1] 谢明君,姜劼琳,葛来安. 健脾和胃行气法治疗晚期消化道恶性肿瘤(脾虚气滞型)化疗引起的消化道不良反应的临床观察[J].中国医学创新,2019,16(29):9-13.
[2] 何伟明,卢光兴,梁碧玉,等. 肿瘤标志物联合检测在消化系统肿瘤中的研究现状及应用前景[J].中国全科医学,2018,21(14):1750-1756.
[3] CANI P D,JORDAN B F. Gut microbiota-mediated inflammation in obesity:a link with gastrointestinal cancer[J].Nat Rev Gastroenterol Hepatol,2018,15(11):671-682.
[4] 崔剑,陈建平,郭芳,等. 盐酸羟考酮缓释片在中重度成人癌痛门诊治疗中的疗效及安全性[J].山西医科大学学报,2018,49(3):297-301.
[5] STEWART J E.The effect of guideline implementation on discharge analgesia prescribing (two years on)[J].Anaesth Intensive Care,2019,47(1):40-44.
[6] 刘海波,胡大勇,周娟,等. 盐酸羟考酮缓释片不同给药途径治疗中重度癌痛的临床观察[J].现代肿瘤医学,2018,26(12):1917-1921.
[7] 孙燕.内科肿瘤学[M].北京:人民卫生出版社,2001:226-227.
[8] 李红姬,金载勇. 大剂量羟考酮缓释片在晚期癌症疼痛治疗中的效果探讨[J].中西医结合心血管病电子杂志,2018,6(29):158-159.
[9] KELLNER R,UHLENHUTH E H. The rating and self-rating of anxiety[J].Br J Psychiatry Suppl,1991,1(12):15-22.
[10] ZUNG W W. A self-rating depression scale[J].Arch Gen Psychiatry,1965,12(12):63.
[11] 沈晓红,姜乾金.医学应对方式问卷中文版701例测试报告[J].中国行为医学科学,2000,9(1):22-24.
[12] 梁靓. 阿帕替尼用于二线及以上治疗失败的晚期或转移性消化道肿瘤患者的近期疗效及不良反应[J].临床医药文献电子杂志,2018,5(A1):102-103.
[13] 宋占峰. 腹腔镜微创手术治疗消化道肿瘤的临床效果及经济效益评估[J].山西医药杂志,2018,47(24):2955-2957.
[14] 邹荣. PTEN在消化系统恶性肿瘤中的研究进展[J].疑难病杂志,2017,16(3):317-320.
[15] GOMES T,JAIN S,PATERSON J M,et al. Trends and uptake of new formulations of controlled-release oxycodone in Canada[J].Pharmacoepidemiol Drug Saf,2018,27(5):520-525.
[16] 李改英,李薇,苏延军,等. 盐酸羟考酮缓释片治疗晚期恶性肿瘤中重度疼痛的临床效果[J].中国医药导报,2017,14(14):92-95.
[17] 黄超妹,李杏欢,潘晓平.大剂量羟考酮缓释片治疗晚期癌痛的效果观察及VAS评分影响评价[J].北方药学,2020,17(1):4-5.
[18] 陈建平,宫霄雯,郑柏华.胃肠癌患者术后抑郁反应对细胞免疫功能的影响[J].中国临床康复,2003,7(23):3238-3239.
[19] 林静华,焦晓阳,吴映娥.肿瘤患者外周血T淋巴细胞和NK细胞检测的意义[J].中国热带医学,2008,8(7):1166-1167.
[20] 崔雅静,宁军. 疼痛控制对中晚期恶性肿瘤患者焦虑抑郁情绪及生活质量的影响[J].北京医学,2018,40(1):91-92.
[21] 刘多.大剂量羟考酮缓释片治疗晚期癌症疼痛的疗效及安全性分析[J].现代医学与健康研究电子杂志,2018,2(13):33.
2022, Vol. 39 
